

# **Peginterferon Alfa-2b Powder Formulation**

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.2 06.04.2024 20506-00025 Date of first issue: 09.10.2014

**SECTION 1: IDENTIFICATION** 

Product name : Peginterferon Alfa-2b Powder Formulation

Manufacturer or supplier's details

Company : MSD

Address : Building A - Level 1/26 Talavera Rd

Macquarie Park NSW, Australia 2113

Telephone : 1 800 033 461

Emergency telephone number : Poisons Information Centre: Phone 13 11 26

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

## **SECTION 2. HAZARDS IDENTIFICATION**

**GHS Classification** 

Reproductive toxicity : Category 1B

**GHS** label elements

Hazard pictograms :

Signal word : Danger

Hazard statements : H360FD May damage fertility. May damage the unborn child.

Precautionary statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

Storage:

P405 Store locked up.



# **Peginterferon Alfa-2b Powder Formulation**

Version SDS Number: Date of last issue: 26.09.2023 Revision Date: 20506-00025 5.2 06.04.2024 Date of first issue: 09.10.2014

#### Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

#### Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

## **SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Sucrose	57-50-1	>= 60 -<= 100
Peginterferon Alfa-2b	215647-85-1	>= 0.3 -< 1

#### **SECTION 4. FIRST AID MEASURES**

General advice In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled, remove to fresh air. If inhaled

Get medical attention.

In case of skin contact In case of contact, immediately flush skin with soap and plenty

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

If in eyes, rinse well with water. In case of eye contact

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms

and effects, both acute and

Protection of first-aiders

delayed

May damage fertility. May damage the unborn child.

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

#### **SECTION 5. FIREFIGHTING MEASURES**

Suitable extinguishing media : Water spray

Alcohol-resistant foam



# **Peginterferon Alfa-2b Powder Formulation**

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.2 06.04.2024 20506-00025 Date of first issue: 09.10.2014

Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

: None known.

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Metal oxides

Phosphorus compounds Oxides of phosphorus

Carbon oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

#### **SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protec: :

tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### **SECTION 7. HANDLING AND STORAGE**



# **Peginterferon Alfa-2b Powder Formulation**

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.2 06.04.2024 20506-00025 Date of first issue: 09.10.2014

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust. Do not swallow.

Avoid contact with eyes.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

Conditions for safe storage : Keep in properly labelled containers.

Store locked up. Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

#### **SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

#### Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Sucrose	57-50-1	TWA	10 mg/m3	AU OEL
		TWA	10 mg/m3	ACGIH
Peginterferon Alfa-2b	215647-85-1	TWA (inhal- able fraction)	0.2 µg/m3 (OEB 5)	Internal

**Engineering measures** : Minimize workplace exposure concentrations.

Apply measures to prevent dust explosions.

Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment). If sufficient ventilation is unavailable, use with local exhaust



# **Peginterferon Alfa-2b Powder Formulation**

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.2 06.04.2024 20506-00025 Date of first issue: 09.10.2014

ventilation.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type

Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending

on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the

end of workday.

Eye protection : Wear the following personal protective equipment:

Safety goggles

Skin and body protection : Select appropriate protective clothing based on chemical

resistance data and an assessment of the local exposure

potential.

Skin contact must be avoided by using impervious protective

clothing (gloves, aprons, boots, etc).

#### **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance : powder

Colour : White to light yellow

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling :

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) : No data available



# **Peginterferon Alfa-2b Powder Formulation**

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.2 06.04.2024 20506-00025 Date of first issue: 09.10.2014

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Density : 1 g/cm<sup>3</sup>

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, dynamic : No data available

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : No data available

## **SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Incompatible materials

Hazardous decomposition

Oxidizing agents

products

No hazardous decomposition products are known.



# **Peginterferon Alfa-2b Powder Formulation**

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.2 06.04.2024 20506-00025 Date of first issue: 09.10.2014

#### **SECTION 11. TOXICOLOGICAL INFORMATION**

Exposure routes : Inhalation

Skin contact Ingestion Eye contact

**Acute toxicity** 

Not classified based on available information.

**Components:** 

Sucrose:

Acute oral toxicity : LD50 (Rat): 29,700 mg/kg

Peginterferon Alfa-2b:

Acute toxicity (other routes of:

administration)

LD50 (Rat): > 20.1 mg/kg Application Route: Intravenous

LD50 (Monkey): > 9.8 mg/kg

Skin corrosion/irritation

Not classified based on available information.

**Components:** 

Peginterferon Alfa-2b:

Species : Rabbit

Result : Mild skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

**Components:** 

Peginterferon Alfa-2b:

Species : Rabbit

Result : Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.



# **Peginterferon Alfa-2b Powder Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 26.09.2023

 5.2
 06.04.2024
 20506-00025
 Date of first issue: 09.10.2014

## **Chronic toxicity**

# Germ cell mutagenicity

Not classified based on available information.

## **Components:**

Sucrose:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Peginterferon Alfa-2b:

Genotoxicity in vitro : Test Type: reverse mutation assay

Result: negative

Test Type: Chromosomal aberration Test system: Human lymphocytes

Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test

Species: Mouse Result: negative

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

May damage fertility. May damage the unborn child.

**Components:** 

Peginterferon Alfa-2b:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Monkey, female

Application Route: Subcutaneous Dose: 0.35 milligram per kilogram Symptoms: Effect on estrous cycle

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on

animal experiments., Clear evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Components:

Peginterferon Alfa-2b:

Target Organs : Gastrointestinal tract, Immune system, Cardio-vascular sys-



# **Peginterferon Alfa-2b Powder Formulation**

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.2 06.04.2024 20506-00025 Date of first issue: 09.10.2014

tem, Endocrine system, Central nervous system, Liver, Res-

piratory Tract, Eye

Assessment : Causes damage to organs through prolonged or repeated

exposure.

# Repeated dose toxicity

#### **Components:**

#### Peginterferon Alfa-2b:

Species : Mouse
NOAEL : 0.0038 mg/kg
Application Route : Subcutaneous

Exposure time : 9 d

Species : Rat

NOAEL : 0.0042 mg/kg Application Route : Subcutaneous

Exposure time : 30 d

Species : Monkey
LOAEL : 0.12 mg/kg
Application Route : Subcutaneous

Exposure time : 30 d

Target Organs : Blood, Bone marrow, Immune system

Species : Monkey
NOAEL : 0.015 mg/kg
LOAEL : 0.077 mg/kg
Exposure time : 3 Months

Target Organs : Respiratory Tract, Cardio-vascular system, Central nervous

system, Bone marrow

## **Aspiration toxicity**

Not classified based on available information.

# Experience with human exposure

## **Components:**

## Peginterferon Alfa-2b:

Inhalation : Symptoms: flu-like symptoms, Gastrointestinal disturbance,

mental depression, tingling



# **Peginterferon Alfa-2b Powder Formulation**

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.2 06.04.2024 20506-00025 Date of first issue: 09.10.2014

#### **SECTION 12. ECOLOGICAL INFORMATION**

**Ecotoxicity** 

**Components:** 

Peginterferon Alfa-2b:

**Ecotoxicology Assessment** 

Acute aquatic toxicity : No data available

Chronic aquatic toxicity : No data available

Persistence and degradability

**Components:** 

Peginterferon Alfa-2b:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 63 % Exposure time: 28 d

Method: OECD Test Guideline 301B

Bioaccumulative potential

**Components:** 

Sucrose:

Partition coefficient: n-

octanol/water

: Pow: < 1

Mobility in soil

No data available

Other adverse effects

No data available

# **SECTION 13. DISPOSAL CONSIDERATIONS**

**Disposal methods** 

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

## **SECTION 14. TRANSPORT INFORMATION**

**International Regulations** 

**UNRTDG** 



# **Peginterferon Alfa-2b Powder Formulation**

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.2 06.04.2024 20506-00025 Date of first issue: 09.10.2014

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

Environmentally hazardous : no

IATA-DGR

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo : Not applicable

aircraft)

Packing instruction (passen-

ger aircraft)

Not applicable

**IMDG-Code** 

UN number Not applicable Proper shipping name Not applicable Class Not applicable Not applicable Subsidiary risk Not applicable Packing group Labels Not applicable **EmS Code** Not applicable Not applicable Marine pollutant

#### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

## **National Regulations**

**ADG** 

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Hazchem Code : Not applicable

Special precautions for user

Not applicable

## **SECTION 15. REGULATORY INFORMATION**

# Safety, health and environmental regulations/legislation specific for the substance or mix-

Therapeutic Goods (Poisons :

Standard) Instrument

Schedule 6 (Please use the original publication to check for specific uses, specific conditions or threshold limits that might

apply for this chemical)



# **Peginterferon Alfa-2b Powder Formulation**

Version SDS Number: Date of last issue: 26.09.2023 Revision Date: 5.2 06.04.2024 20506-00025 Date of first issue: 09.10.2014

Prohibition/Licensing Requirements : There is no applicable prohibition,

> authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regula-

tions.

The components of this product are reported in the following inventories:

**AICS** not determined

DSL not determined

**IECSC** not determined

#### **SECTION 16: ANY OTHER RELEVANT INFORMATION**

## **Further information**

**Revision Date** 06.04.2024

Sources of key data used to

compile the Safety Data

Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Date format dd.mm.yyyy

#### Full text of other abbreviations

**ACGIH** USA. ACGIH Threshold Limit Values (TLV)

**AU OEL** Australia. Workplace Exposure Standards for Airborne Con-

taminants.

ACGIH / TWA 8-hour, time-weighted average

Exposure standard - time weighted average AU OEL / TWA

AIIC - Australian Inventory of Industrial Chemicals: ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk, IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect



# **Peginterferon Alfa-2b Powder Formulation**

Version Revision Date: SDS Number: Date of last issue: 26.09.2023 5.2 06.04.2024 20506-00025 Date of first issue: 09.10.2014

Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN